Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: In vitro and in vivo investigations

Journal of Nanobiotechnology

Volumn 14, Issue 1, 2016, Pages

  Fasehee, Hamidreza ^a   Dinarvand, Rassoul ^b   Ghavamzadeh, Ardeshir ^c   Esfandyari Manesh, Mehdi ^d   Moradian, Hanieh ^a,d   Faghihi, Shahab ^a   Ghaffari, Seyed Hamidollah ^c  

^a NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

Author keywords

Apoptosis; Breast cancer cells; Disulfiram; Folate receptor; PLGA nanoparticles; Targeted drug delivery

Indexed keywords

CELL DEATH; CELL PROLIFERATION; CYTOLOGY; DISEASES; NANOPARTICLES; TOXICITY; TUMORS;

BREAST CANCER CELLS; DISULFIRAM; FOLATE RECEPTOR; PLGA NANOPARTICLES; TARGETED DRUG DELIVERY;

CELLS;

DISULFIRAM; FOLATE RECEPTOR; MACROGOL; NANOPARTICLE; POLYGLACTIN; REACTIVE OXYGEN METABOLITE; DRUG CARRIER; FOLIC ACID; LACTIC ACID; MACROGOL DERIVATIVE; POLY(ETHYLENE GLYCOL)-FOLATE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN TARGETING; TOXICITY TESTING; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; FEMALE; HUMAN; MCF-7 CELL LINE; METABOLISM; PARTICLE SIZE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DISULFIRAM; DRUG CARRIERS; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HUMANS; LACTIC ACID; MCF-7 CELLS; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID;

EID: 84963805993     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-016-0183-z     Document Type: Article

References (32)

1. Chen D, et al. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006;66(21):10425-33.
2. Cvek B. Comment on 'cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells'. Br J Cancer. 2013;108(4):993.
3. Conticello C, et al. Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. Int J Cancer. 2012;131(9):2197-203.
4. Chen D, Dou QP. New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer. Expert Opin Ther Targets. 2008;12(6):739-48.
5. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer. 2003;104(4):504-11.
6. Lin J, et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 2011;71(4):333-43.
7. Iljin K, et al. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res. 2009;15(19):6070-8.
8. Yip NC, et al. Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer. 2011;104(10):1564-74.
9. Cvek B, Dvorak Z. Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals. Curr Pharm Des. 2007;13(30):3155-67.
10. Skrott Z, Cvek B. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. Mini Rev Med Chem. 2012;12(12):1184-92.
11. Guo X, et al. Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Lett. 2010;290(1):104-13.
12. Liu P, et al. Reply: cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer. 2013;108(4):994.
13. Duan L, et al. Inhibitory effect of disulfiram/copper complex on non-small cell lung cancer cells. Biochem Biophys Res Commun. 2014;446(4):1010-6.
14. Duan X, et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano. 2013;7(7):5858-69.
15. Duan X, et al. Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram. Nanotechnology. 2014;25(12):125102.
16. Liu P, et al. Liposome encapsulated disulfiram inhibits NFkappaB pathway and targets breast cancer stem cells in vitro and in vivo. Oncotarget. 2014;5(17):7471-85.
17. Danhier F, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-22.
18. Esmaeili F, et al. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target. 2008;16(5):415-23.
19. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63(3):170-83.
20. Dinarvand R, et al. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomed. 2011;6:877-95.
21. Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012. doi: 10.3402/nano.v3i0.18496.
22. Lewis DJ, et al. On the interaction of copper(II) with disulfiram. Chem Commun (Camb). 2014;50(87):13334-7.
23. Moradian H, et al. Poly(ethyleneimine) functionalized carbon nanotubes as efficient nano-vector for transfecting mesenchymal stem cells. Colloids Surf B Biointerfaces. 2014;122:115-25.
24. Hassani S, et al. Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest. Ann Hematol. 2013;92(9):1207-20.
25. Zha J, et al. Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition. J Transl Med. 2014;12:163.
26. Zhang H, et al. Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res. 2010;70(10):3996-4004.
27. Langroodi FA, et al. Evaluation of the effect of crocetin on antitumor activity of doxorubicin encapsulated in PLGA nanoparticles. Nanomed J. 2016;3(1):23-34.
28. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153(3):198-205.
29. O'Shannessy DJ, et al. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus. 2012;1:22.
30. Panyam J, et al. Polymer degradation and in vitro release of a model protein from poly(d, l-lactide-co-glycolide) nano- and microparticles. J Control Release. 2003;92(1-2):173-87.
31. Gabizon A, Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta. 1992;1103(1):94-100.
32. Belloc F, et al. A flow cytometric method using hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry. 1994;17:59-65.